Skip to main content

Select Drug Profiles

ASCO 2017 - Acute Myeloid Leukemia

Achievement of a Negative MRD State After Hypomethylating Agent Therapy in Older Patients with AML to Reduce Risk of Relapse

ASCO 2017 - Acute Myeloid Leukemia

Assessment of Molecular Response to Gilteritinib in FLT3 Mutation–Positive Relapsed/Refractory Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Distinct Patterns of Somatic Mutation Clearance and Association with Clinical Outcome in Patients with AML

ASCO 2017 - Acute Myeloid Leukemia

Prognostic Modeling to Predict Outcomes in Older Patients with AML

ASCO 2017 - Acute Myeloid Leukemia

A Randomized Phase 2 Study Evaluating Idarubicin and Cytarabine with Clofarabine or Fludarabine in Adults with Newly Diagnosed AML

ASCO 2017 - Acute Myeloid Leukemia

Unsupervised Hierarchical Clustering of Surface Antigen Expression to Identify Patients with Normal Karyotype AML with Distinct Disease Characteristics and Poor Outcome

ASCO 2017 - Acute Myeloid Leukemia

Improved Survival with Fludarabine and Timed Sequential Busulfan Regimen in Older Patients with AML or MDS

ASCO 2017 - Acute Myeloid Leukemia

Allogeneic Transplant Leads to Markedly Improved Survival in Older Patients with Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Nivolumab with Azacytidine in Patients with Relapsed AML

ASCO 2017 - Acute Myeloid Leukemia, Conference Correspondent

Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry

Page 90 of 244
Results 891 - 900 of 2438